Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

MEDRx completes exercise of 35th series warrants, raising ¥718 million

Tue, Nov 17, 2026 17:30 JST MEDRx Co., Ltd. (4586.T) Pharmaceutical 中文

MEDRx Co., Ltd. (4586) said on Nov. 17 that all 147,820 of its 35th series stock acquisition rights issued in June have been exercised, bringing estimated net proceeds to ¥718 million.

Funds raised (estimated net proceeds)¥718 million
Shares delivered in November2,839,600 shares
November exercise price¥44 / ¥37
Shares outstanding (Nov. 17)74,147,100 shares

The warrants, which carry an exercise-price adjustment clause, were issued on June 5, 2026 through a third-party allotment to Growth Capital Co., Ltd. With the payment made on Nov. 17, no unexercised rights remain.

In November, 28,396 rights were exercised, or 19.21% of the total issued, resulting in the delivery of 2,839,600 new shares. No treasury shares were used. The exercise price was ¥44 on Nov. 2 and ¥37 from Nov. 9.

ItemFigure
Rights exercised in November28,396
Shares delivered in November2,839,600
November exercise price¥44 / ¥37
Funds raised (estimated net proceeds)¥718 million

Under the exercise restrictions of Tokyo Stock Exchange listing rule 434, shares delivered in November totaled 2,839,600 against 59,365,100 listed shares at the time of issuance payment, an exercise ratio of 4.78%.

Shares outstanding rose to 74,147,100 as of Nov. 17 from 71,307,500 at the end of October, which included two treasury shares. Capital stood at ¥418 million. The company referred readers to its May 20, 2026 announcement for details of the issuance.


Original filings
Related